



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : A.K. Gunnar Aberg
Serial No. : 10/677,527
Filed : October 2, 2003
For : METHODS FOR TREATING URINARY INCONTINENCE AND OTHER DISORDERS USING TROSPiUM
Examiner : Not yet assigned
Art Unit : Not yet assigned
Attorney
Docket No. : 559P021


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Sir:

INFORMATION DISCLOSURE STATEMENT

The Examiner is respectfully requested to consider the documents which are listed on the attached form PTO 1449.

Copies of the documents listed on the attached form are filed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on December 30, 2003




Signature: Kevin S. Lemack
Date: December 30, 2003

Respectfully submitted,



Kevin S. Lemack
Attorney for Applicants
Registration No. 32,579
Nields & Lemack
176 E. Main Street
Westboro, MA 01581
TEL: (508) 898-1818



FORM PTO-1449

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO. 559P021	SERIAL NO. 10/677,527
A.K. Gunnar Aberg	
FILING DATE October 2, 2003	GROUP Not yet assigned

REFERENCE DESIGNATION

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	3,480,626	11/1969	Pfleger et al.	260	247.2	
	AB	5,998,430	12/1999	Schwantes et al.	514	299	
	AC	6,482,837	11/2002	Wood	514	315	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BA							
	BB							
	BB							

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

CA		Pharmacology & Toxicology 1999, 85, 299-304; Svane Beckmann-Knopp et al.; "Inhibitory Effects of Trospium Chloride on Cytochrome P450 Enzymes in Human Liver Microsomes"
CB		Bertholdt H. et al., Arzneimittel-Forsch, 17; 719-726.
CC		Biochemical Pharmacology, Vol. 22, pp. 3099-3108. Pergamon Press, 1973; Yung-Chi Cheng et al.; "Relationship Between the Inhibition Constant (K1) and the Concentration of Inhibitor which causes 50 per cent Inhibition (I50) of an Enzymatic Reaction"
CD		The Lancet; vol. 338; August 10, 1991 pp. 344-345; M.J. Connolly et al.; "Torsades de pointes ventricular tachycardia and terodilane"
CE		Chrysalis; "P.a. Gayheart-Walsten, et al.; "Effects of a New Non-Sedating Antihistamine on QTc Interval in a Newly Developed Guinea Pig Model"
CF		Journal of Cardiovascular Pharmacology; 37: 607-618; 2001; Gary A. Gintant et al.; "The Canine Purkinje Fiber: An In Vitro Model System for Acquired Long QT Syndrome and Drug-Induced Arrhythmogenesis"
CG		Dig Dis 1992; 10: 38-45; Juha M. Gronroos et al.; "Cholinergic Hypothesis of Alcoholic Pancreatitis"
CH		Clinical Pharmacology & Therapeutics July 1996 ; 07019901; pp. 89-98; Kenneth Hartigan-Go, MD et al.; "Stereoselective Cardiotoxic Effects of Terodilane"
CI		Abstracts 487-488; 85A; Hofner et al.; "Tolerability and Efficacy of Trospium Chloride in a Long-Term Treatment (52 weeks) in Patients with Urge-Syndrome: A Double-Blind, Controlled, Multicentre Clinical Trial"
CJ		Ital Heart J. Suppl. 2000; 1 (3): 419-422; Imperadore et al.; "Arresto cardiaco da fibrillazione ventricolare in corso di pancreatite acuta biliare: descrizione di un caso clinico e ipotesi eziopatogenetiche"
CK		Page from Medscape from WEBMD; Rhythm disorders in gallstones;

	CL	British Journal of Pharmacology (2000) 131, 245-254; Stephen E. Jones et al.; "Differences in the effects of urinary incontinence agents S-oxybutynin and terodilane on cardiac K ⁺ currents and action potentials"
	CM	The Journal of Pharmacology and Experimental Therapeutics; vol. 247, No. 3; pp. 867-872; James F. Kachur et al.; "R and S Enantiomers of Oxybutynin: Pharmacological Effects in Guinea Pig Bladder and Intestine"
	CN	Pharmacology & Toxicology 1998, 82, 161-166; Eeva Lukkari et al.; "Cytochrome P450 Specificity of Metabolism and Interactions of Oxybutynin in Human Liver Microsomes"
	CO	British Journal of Urology (1995), 75, 452-456; H. Maderscacher et al.; "Trospium Chloride Versus Oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia"
	CP	The Journal of Urology; Vol. 148, 595-597, August 1992; Charlotte A. Massad et al.; "The Pharmacokinetics of Intravesical and Oral Oxybutynin Chloride"
	CQ	The Journal of Pharmacology and Experimental Therapeutics; Vol. 256, No. 2; L.Noronha-Blob et al.; "Enantiomers of Oxybutynin: In Vitro Pharmacological Characterization at M1, M2 and M3 Muscarinic Receptors and in Vivo Effects on Urinary Bladder Contraction, Mydriasis and Salivary Secretion in Guinea Pigs"
	CR	Bur J Clin Pharmacol (1994) 47: 337-343; A. Pietzko et al.; "Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers"
	CS	Drug Metabolism and Disposition Vol. 26, No. 4 pp. 289-293; Hans Postlind et al.; "Tolterodine, A New Muscarinic Receptor Antagonist, Is Metabolized by Cytochromes P450 2D6 and 3A in Human Liver Microsomes"
	CT	The Journal of Pharmacology and Experimental Therapeutics; Vol. 290, No. 3; pp. 1417-1426; Shuba et al.; "Action Potentials, Contraction, and Membrane Currents in Guinea Pigs Ventricular Preparations Treated with the Antispasmodic Agent Terodilane"
	CU	Arzneimittel-Forschung/Drug Research 48 (11), 10, 1012-1018 (1998); Smith et al. "Comparison of the Antimuscarinic and Antispasmodic Actions of Racemic Oxybutynin and Desethyloxybutynin and Their Enantiomers with Those of Racemic Terodilane"
	CV	Page from Medscape from WEB MD; "Effects of Tolterodine, Trospium Chloride, and oxybutynin on the central nervous system"
	CW	Clin Drug Invest 23(6); 395-404, 2003; Diefenbach et al.; "Randomised, Double-Blind Study of the Effects of Oxybutynin, Tolterodine, Trospium Chloride and Placebo on Sleep in Healthy Young Volunteers".

EXA MINER: Initial reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box →

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

O P E
J C
JAN 12 2003
PATENT & TRADEMARK OFFICE

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/677,527
Filing Date	October 2, 2003
First Named Inventor	A.K. Gunnar Aberg
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Total Number of Pages in This Submission	559P021

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	-Form PTO-1449
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	-References cited - 26
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Kevin S. Lemack Nields & Lemack
Signature	
Date	December 30, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date:

Typed or printed name	Kevin S. Lemack
Signature	
Date	December 30, 2003

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.